Economic analysis of insulin initiation by pharmacists in a Canadian setting
暂无分享,去创建一个
R. Tsuyuki | Y. A. Al Hamarneh | Stephen T Brown | L. Sauriol | Kimberley Nehme | Yazid N. Al Hamarneh
[1] R. Tsuyuki,et al. Pharmacist intervention for glycaemic control in the community (the RxING study) , 2013, BMJ Open.
[2] V. Woo,et al. Pharmacologic management of type 2 diabetes. , 2013, Canadian journal of diabetes.
[3] D. Wright,et al. Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysis , 2011, Journal of medical economics.
[4] A. Willan,et al. Clinical inertia in patients with T2DM requiring insulin in family practice. , 2010, Canadian family physician Medecin de famille canadien.
[5] C. Cameron,et al. Cost-effectiveness of insulin analogues for diabetes mellitus , 2009, Canadian Medical Association Journal.
[6] Carl van Walraven,et al. Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? , 2005, Diabetes care.
[7] Volker Foos,et al. The CORE Diabetes Model: Projecting Long-term Clinical Outcomes, Costs and Costeffectiveness of Interventions in Diabetes Mellitus (Types 1 and 2) to Support Clinical and Reimbursement Decision-making , 2004, Current medical research and opinion.
[8] J. Caro,et al. Cost of managing complications resulting from type 2 diabetes mellitus in Canada , 2003, BMC health services research.
[9] Andreas Laupacis,et al. Inclusion of drugs in provincial drug benefit programs: who is making these decisions, and are they the right ones? , 2002, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[10] Lawrence A Leiter,et al. Out-of-pocket Costs of Managing Hyperglycemia and Hypoglycemia in Patients With Type 1 Diabetes and Insulin-treated Type 2 Diabetes , 2007 .